

# Kathryn Pritchard-Jones

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3537344/publications.pdf>

Version: 2024-02-01

308  
papers

17,783  
citations

11908

72  
h-index

22488

117  
g-index

323  
all docs

323  
docs citations

323  
times ranked

15674  
citing authors

#	ARTICLE	IF	CITATIONS
1	International variation in childhood cancer mortality rates from 2001 to 2015: Comparison of trends in the International Cancer Benchmarking Partnership countries. <i>International Journal of Cancer</i> , 2022, 150, 28-37.	2.3	6
2	Surgical management, staging, and outcomes of Wilms tumours with intravascular extension: Results of the IMPORT study. <i>Journal of Pediatric Surgery</i> , 2022, 57, 572-578.	0.8	7
3	The epithelial splicing regulator <i>ESRP2</i> is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor. <i>Molecular Oncology</i> , 2022, 16, 630-647.	2.1	3
4	Long-term kidney function in children with Wilms tumour and constitutional WT1 pathogenic variant. <i>Pediatric Nephrology</i> , 2022, 37, 821-832.	0.9	5
5	Impact of the COVID-19 pandemic on pediatric oncology providers globally: A mixed-methods study. <i>Cancer</i> , 2022, 128, 1493-1502.	2.0	17
6	Characteristics and outcomes of preoperatively treated patients with anaplastic Wilms tumors registered in the UK SIOP-WT-2001 and IMPORT study cohorts (2002-2020). <i>Cancer</i> , 2022, 128, 1666-1675.	2.0	6
7	Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only ~ the SIOP 93-01 and 2001 protocols. <i>European Journal of Cancer</i> , 2022, 163, 88-97.	1.3	8
8	SIOP Strategy 2021-2025: Cure for more, care for all. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29577.	0.8	2
9	Treatment of patients with stage I focal anaplastic and diffuse anaplastic Wilms tumour: A report from the SIOP-WT-2001 GPOH and UK-CCLG studies. <i>European Journal of Cancer</i> , 2022, 166, 1-7.	1.3	0
10	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. <i>Cancer Discovery</i> , 2022, 12, 331-355.	7.7	70
11	Loss associated with subtractive health service change: The case of specialist cancer centralization in England. <i>Journal of Health Services Research and Policy</i> , 2022, 27, 301-312.	0.8	6
12	International Comparisons of Clinical Demographics and Outcomes in the International Society of Pediatric Oncology Wilms Tumor 2001 Trial and Study. <i>JCO Global Oncology</i> , 2022, 8, e2100425.	0.8	14
13	How we approach paediatric renal tumour core needle biopsy in the setting of preoperative chemotherapy: A Review from the SIOP Renal Tumour Study Group. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29702.	0.8	9
14	The clinical impact of observer variability in lung nodule classification in children with Wilms tumour. <i>Pediatric Blood and Cancer</i> , 2022, 69, .	0.8	2
15	Implementing major system change in specialist cancer surgery: The role of provider networks. <i>Journal of Health Services Research and Policy</i> , 2021, 26, 4-11.	0.8	11
16	Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30-year SIOP-RTSG experience. <i>Cancer</i> , 2021, 127, 628-638.	2.0	30
17	Outcome of Stage IV Completely Necrotic Wilms Tumour and Local Stage III Treated According to the SIOP 2001 Protocol. <i>Cancers</i> , 2021, 13, 976.	1.7	6
18	Characteristics and outcome of pediatric renal cell carcinoma patients registered in the International Society of Pediatric Oncology (SIOP) 93-01, 2001 and UK-IMPORT database: A report of the SIOP-Renal Tumour Study Group. <i>International Journal of Cancer</i> , 2021, 148, 2724-2735.	2.3	26

#	ARTICLE	IF	CITATIONS
19	The Global COVID-19 Observatory and Resource Center for Childhood Cancer: A response for the pediatric oncology community by SIOP and St. Jude Global. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28962.	0.8	8
20	The threat of the COVID-19 pandemic on reversing global life-saving gains in the survival of childhood cancer: a call for collaborative action from SIOP, IPSO, PROS, WCC, CCI, St Jude Global, UICC and WHPCA. <i>Ecancermedicalsecience</i> , 2021, 15, 1187.	0.6	4
21	Predisposition to cancer in children and adolescents. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 142-154.	2.7	53
22	Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 332-340.	2.7	83
23	How to Cost the Implementation of Major System Change for Economic Evaluations: Case Study Using Reconfigurations of Specialist Cancer Surgery in Part of London, England. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 797-810.	1.0	4
24	Comparative analysis of the clinical characteristics and outcomes of patients with Wilms tumor in the United Kingdom and Japan. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29143.	0.8	7
25	Staging childhood cancers in Europe: Application of the Toronto stage principles for neuroblastoma and Wilms tumour. The JARC pilot study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29020.	0.8	7
26	Prognostic significance of histopathological response to preoperative chemotherapy in unilateral Wilms' tumor: An analysis of 899 patients treated on the SIOP WT 2001 protocol in the UK CCLG and GPOH studies. <i>International Journal of Cancer</i> , 2021, 149, 1332-1340.	2.3	16
27	Oral etoposide as a single agent in childhood and young adult cancer in England: Still a poorly evaluated palliative treatment. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29204.	0.8	2
28	Wilms tumour surveillance in at-risk children: Literature review and recommendations from the SIOP-Europe Host Genome Working Group and SIOP Renal Tumour Study Group. <i>European Journal of Cancer</i> , 2021, 153, 51-63.	1.3	25
29	Fifty years of clinical and research studies for childhood renal tumors within the International Society of Pediatric Oncology (SIOP). <i>Annals of Oncology</i> , 2021, 32, 1327-1331.	0.6	14
30	Pediatric cancer care in Africa: SIOP Global Mapping Program report on economic and population indicators. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29345.	0.8	10
31	Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 1416-1426.	5.1	93
32	The multidisciplinary, theory-based co-design of a new digital health intervention supporting the care of oesophageal cancer patients. <i>Digital Health</i> , 2021, 7, 205520762110384.	0.9	7
33	Wilms tumour. <i>Nature Reviews Disease Primers</i> , 2021, 7, 75.	18.1	75
34	Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWITS, and UKCCSG. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28039.	0.8	14
35	Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review. <i>Cancers</i> , 2020, 12, 1776.	1.7	29
36	Working Together to Build a Better Future for Children With Cancer in Africa. <i>JCO Global Oncology</i> , 2020, 6, 1076-1078.	0.8	13

#	ARTICLE	IF	CITATIONS
37	Pediatric and young adult renal cell carcinoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28675.	0.8	14
38	The COVID-19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28409.	0.8	113
39	Incidence of childhood renal tumours: An international population-based study. <i>International Journal of Cancer</i> , 2020, 147, 3313-3327.	2.3	73
40	Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28327.	0.8	93
41	Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group. <i>European Journal of Cancer</i> , 2020, 128, 38-46.	1.3	24
42	An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. <i>Nature Communications</i> , 2020, 11, 1310.	5.8	183
43	The role of imaging in the initial investigation of paediatric renal tumours. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 232-241.	2.7	25
44	Sustainable care for children with cancer: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2020, 21, e185-e224.	5.1	177
45	Prognostic significance of age in 5631 patients with Wilms tumour prospectively registered in International Society of Paediatric Oncology (SIOP) 93-01 and 2001. <i>PLoS ONE</i> , 2019, 14, e0221373.	1.1	33
46	The genetic changes of Wilms tumour. <i>Nature Reviews Nephrology</i> , 2019, 15, 240-251.	4.1	159
47	Highlights from the 13th African Continental Meeting of the International Society of Paediatric Oncology (SIOP), 6-9 March 2019, Cairo, Egypt. <i>Ecancermedicalscience</i> , 2019, 13, 932.	0.6	6
48	The European study on centralisation of childhood cancer treatment. <i>European Journal of Cancer</i> , 2019, 115, 120-127.	1.3	12
49	Evaluation of needle biopsy as a potential risk factor for local recurrence of Wilms tumour in the SIOP WT 2001 trial. <i>European Journal of Cancer</i> , 2019, 116, 13-20.	1.3	24
50	Reply to the Letter to the Editor: Renal tumors in children older than 10 years "Should we be doing upfront nephrectomy?". <i>Pediatric Blood and Cancer</i> , 2019, 66, e27760.	0.8	0
51	Stage at diagnosis for childhood solid cancers in Australia: A population-based study. <i>Cancer Epidemiology</i> , 2019, 59, 208-214.	0.8	12
52	Science and health for all children with cancer. <i>Science</i> , 2019, 363, 1182-1186.	6.0	200
53	WARNING: G401 and SK-NEP cell lines are not Wilms tumor cell lines. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27741.	0.8	10
54	Comment on: "Indications and results of diagnostic biopsy in pediatric renal tumors: A retrospective analysis of 317 patients with critical review of SIOP guidelines". <i>Pediatric Blood and Cancer</i> , 2019, 66, e27746.	0.8	1

#	ARTICLE	IF	CITATIONS
55	The diagnostic accuracy and clinical utility of pediatric renal tumor biopsy: Report of the UK experience in the SIOP UK WT 2001 trial. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27627.	0.8	41
56	Embryonal precursors of Wilms tumor. <i>Science</i> , 2019, 366, 1247-1251.	6.0	101
57	Pharmacotherapeutic Management of Wilms Tumor: An Update. <i>Paediatric Drugs</i> , 2019, 21, 1-13.	1.3	23
58	Outcomes of non-anaplastic stage III and "inoperable" Wilms tumour treated in the UKW3 trial. <i>Radiotherapy and Oncology</i> , 2019, 131, 1-7.	0.3	7
59	Evidence-based data and rare cancers: The need for a new methodological approach in research and investigation. <i>European Journal of Surgical Oncology</i> , 2019, 45, 22-30.	0.5	16
60	Rationale for the treatment of children with CCSK in the UMBRELLA SIOP-RTSG 2016 protocol. <i>Nature Reviews Urology</i> , 2018, 15, 309-319.	1.9	43
61	Childhood cancer incidence and survival in Japan and England: A population-based study (1993-2010). <i>Cancer Science</i> , 2018, 109, 422-434.	1.7	73
62	Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP-WT-2001 Registry. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27085.	0.8	10
63	Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature. A report from the SIOP Renal Tumor Study Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26849.	0.8	11
64	Follow-up surveillance of Wilm's tumour " Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e503.	5.1	0
65	The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. <i>Nature Reviews Urology</i> , 2018, 15, 693-701.	1.9	152
66	Relapse of Wilms' tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group "International Society of Paediatric Oncology Wilms' tumour protocol database. <i>Lancet Oncology</i> , The, 2018, 19, 1072-1081.	5.1	59
67	Congenital mesoblastic nephroma 50 years after its recognition: A narrative review. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26437.	0.8	84
68	Review of phase I and II trials for Wilms' tumour " Can we optimise the search for novel agents?. <i>European Journal of Cancer</i> , 2017, 79, 205-213.	1.3	25
69	Nephrogenic rests in Wilms tumors treated with preoperative chemotherapy: The UK SIOP Wilms Tumor 2001 Trial experience. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26547.	0.8	28
70	Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis. <i>Fetal and Pediatric Pathology</i> , 2017, 36, 62-75.	0.4	18
71	Bilateral Wilms tumour: a review of clinical and molecular features. <i>Expert Reviews in Molecular Medicine</i> , 2017, 19, e8.	1.6	79
72	Integrating genomics to dig deeper into Wilms tumour biology. <i>Nature Reviews Urology</i> , 2017, 14, 703-704.	1.9	4

#	ARTICLE	IF	CITATIONS
73	Rationale for the treatment of Wilms tumour in the UMBRELLA SIOPâ€“RTSG 2016 protocol. <i>Nature Reviews Urology</i> , 2017, 14, 743-752.	1.9	249
74	Wilmsâ€™ Tumor. , 2017, , 4850-4853.		0
75	The clinical phenotype of <sc><i>YWHAEâ€“UTM2B/E</i></sc> positive pediatric clear cell sarcoma of the kidney. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 143-147.	1.5	14
76	Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines. <i>Lancet Oncology</i> , The, 2016, 17, e163-e172.	5.1	56
77	Risk of Adverse Health and Social Outcomes Up to 50 Years After Wilms Tumor: The British Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1772-1779.	0.8	59
78	European Survey on Standards of Care in paediatric oncology centres. <i>European Journal of Cancer</i> , 2016, 61, 11-19.	1.3	25
79	Ethical issues of clinical trials in paediatric oncology from 2003 to 2013: a systematic review. <i>Lancet Oncology</i> , The, 2016, 17, e187-e197.	5.1	14
80	Biology and treatment of Wilmsâ€™ tumours in childhood. <i>Revue D'Oncologie HÃ©matologie PÃ©diatrique</i> , 2016, 4, 170-181.	0.1	3
81	Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications. <i>EBioMedicine</i> , 2016, 9, 120-129.	2.7	61
82	Wilms tumor: â€œState-of-the-artâ€“ update, 2016. <i>Seminars in Pediatric Surgery</i> , 2016, 25, 250-256.	0.5	85
83	Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3195-3203.	0.8	105
84	Biology and treatment of renal tumours in childhood. <i>European Journal of Cancer</i> , 2016, 68, 179-195.	1.3	107
85	PWE-131â€“The First UK Multidisciplinary Diagnostic Centre: A Novel Cancer Diagnostic Service. <i>Gut</i> , 2016, 65, A202.2-A203.	6.1	1
86	Evidence for a delay in diagnosis of Wilmsâ€™ tumour in the UK compared with Germany: implications for primary care for children. <i>Archives of Disease in Childhood</i> , 2016, 101, 417-420.	1.0	35
87	Reorganising specialist cancer surgery for the twenty-first century: a mixed methods evaluation (RESPECT-21). <i>Implementation Science</i> , 2016, 11, 155.	2.5	18
88	The SIOPE strategic plan: A European cancer plan for children and adolescents. <i>Journal of Cancer Policy</i> , 2016, 8, 17-32.	0.6	57
89	WT1 Mutation in Childhood Cancer. <i>Methods in Molecular Biology</i> , 2016, 1467, 1-14.	0.4	17
90	256 Integrated analysis of DNA methylation, copy number and expression data in Wilms Tumour identifies subtype-specific molecular signatures. <i>European Journal of Cancer</i> , 2015, 51, S45.	1.3	0

#	ARTICLE	IF	CITATIONS
91	1407 The European Strategic Plan for children and adolescents with cancer. <i>European Journal of Cancer</i> , 2015, 51, S200.	1.3	0
92	Response to the letter to the editor: 1q gain is a frequent finding in preoperatively treated <sc>W</sc>ilms tumors, but of limited prognostic value for risk satisfaction in the <sc>SIOP</sc>2009/<sc>Gesellschaft f�r P�diatrische Onkologie und H�matologie (GPOH)</sc> trial. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 397-399.	1.5	2
93	A multi�Gaussian model for apparent diffusion coefficient histogram analysis of Wilms�TM tumour subtype and response to chemotherapy. <i>NMR in Biomedicine</i> , 2015, 28, 948-957.	1.6	34
94	The yin and yang of kidney development and Wilms�TM tumors. <i>Genes and Development</i> , 2015, 29, 467-482.	2.7	129
95	Risk factors for local recurrence in Wilms tumour and the potential influence of biopsy �� The United Kingdom experience. <i>European Journal of Cancer</i> , 2015, 51, 225-232.	1.3	47
96	Mutations in the SIX1/2 Pathway and the DROSHA/DGCR8 miRNA Microprocessor Complex Underlie High-Risk Blastemal Type Wilms Tumors. <i>Cancer Cell</i> , 2015, 27, 298-311.	7.7	248
97	Biomarkers to detect Wilms tumors in pediatric patients: where are we now?. <i>Future Oncology</i> , 2015, 11, 2221-2234.	1.1	18
98	Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG). <i>European Journal of Cancer</i> , 2015, 51, 498-506.	1.3	67
99	Response to letter commenting on ��Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG)��. <i>European Journal of Cancer</i> , 2015, 51, 995-996.	1.3	0
100	Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumour. <i>Genome Medicine</i> , 2015, 7, 11.	3.6	39
101	Long-term effects of Wilms tumour therapy on renal function. <i>Nature Reviews Urology</i> , 2015, 12, 423-424.	1.9	2
102	Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. <i>Journal of Clinical Oncology</i> , 2015, 33, 2999-3007.	0.8	281
103	Omission of doxorubicin from the treatment of stage II��III, intermediate-risk Wilms' tumour (SIOP WT) Tj ETQq1 1 0.784314 rgBT / 6.3 165	6.3	165
104	Multiple mechanisms of MYCN dysregulation in Wilms tumour. <i>Oncotarget</i> , 2015, 6, 7232-7243.	0.8	85
105	Wilms�TM Tumor., 2015, , 1-4.		0
106	Abstract A1-59: Multiple mechanisms of MYCN dysregulation in Wilms tumor., 2015, , .		1
107	Abstract A1-67: Prognostic significance of copy number aberrations in Wilms tumor., 2015, , .		0
108	TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia. <i>PLoS ONE</i> , 2014, 9, e109924.	1.1	82

#	ARTICLE	IF	CITATIONS
109	Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood. <i>Genome Biology</i> , 2014, 15, 434.	3.8	33
110	Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney: a combined SIOP and AIEOP study. <i>British Journal of Cancer</i> , 2014, 111, 227-233.	2.9	49
111	Why should survivors of childhood renal tumor and others with only one kidney be denied the chance to play contact sports?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 363-366.	1.1	5
112	Drug discovery in paediatric oncology: roadblocks to progress. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 732-739.	12.5	28
113	Declining childhood and adolescent cancer mortality: Great progress but still much to be done. <i>Cancer</i> , 2014, 120, 2388-2391.	2.0	27
114	Toxicity and Outcome of Children and Adolescents Participating in Phase I/II Trials of Novel Anticancer Drugs. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, 218-223.	0.3	25
115	Towards reducing inequalities: European Standards of Care for Children with Cancer. <i>European Journal of Cancer</i> , 2014, 50, 481-485.	1.3	36
116	Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour. <i>Nature Communications</i> , 2014, 5, 4398.	5.8	85
117	Nephron sparing surgery (NSS) for unilateral wilms tumor (UWT): The SIOP 2001 experience. <i>Pediatric Blood and Cancer</i> , 2014, 61, 2175-2179.	0.8	85
118	Lin28 sustains early renal progenitors and induces Wilms tumor. <i>Genes and Development</i> , 2014, 28, 971-982.	2.7	149
119	Outcome of localized blastemal-type nephroblastoma patients treated according to intensified treatment in the SIOP 2001 protocol: A report of the SIOP-RTSG.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10002-10002.	0.8	1
120	Learning what high quality compassionate care means for cancer patients and translating that into practice. <i>Patient Experience Journal</i> , 2014, 1, 124-131.	0.3	5
121	Wilms' tumor: biology, diagnosis and treatment. <i>Translational Pediatrics</i> , 2014, 3, 12-24.	0.5	100
122	Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney (CCSK): A combined SIOP and AIEOP study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10041-10041.	0.8	1
123	Incidence and outcomes of patients with late recurrence of Wilms' tumor. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1612-1615.	0.8	43
124	New policies to address the global burden of childhood cancers. <i>Lancet Oncology</i> , The, 2013, 14, e125-e135.	5.1	96
125	Surgical complications after immediate nephrectomy versus preoperative chemotherapy in non-metastatic Wilms' tumour: Findings from the 1991-2001 United Kingdom Children's Cancer Study Group UKW3 Trial. <i>Journal of Pediatric Surgery</i> , 2013, 48, 2181-2186.	0.8	31
126	Is Wilms Tumor a Candidate Neoplasia for Treatment with WNT/ $\beta^2$ -Catenin Pathway Modulators?â€”A Report from the Renal Tumors Biology-Driven Drug Development Workshop. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2619-2627.	1.9	28



#	ARTICLE	IF	CITATIONS
127	Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. <i>Lancet Oncology</i> , The, 2013, 14, e95-e103.	5.1	175
128	Children with cancer: driving the global agenda. <i>Lancet Oncology</i> , The, 2013, 14, 189-191.	5.1	35
129	An international strategy to determine the role of high dose therapy in recurrent Wilms's tumour. <i>European Journal of Cancer</i> , 2013, 49, 194-210.	1.3	61
130	SIOP PODC: Clinical guidelines for the management of children with Wilms tumour in a low income setting. <i>Pediatric Blood and Cancer</i> , 2013, 60, 5-11.	0.8	81
131	Treatment of high risk Sertoli-Leydig cell tumors of the ovary using a gonadotropin releasing hormone (GnRH) analog. <i>Pediatric Blood and Cancer</i> , 2013, 60, E16-8.	0.8	9
132	Treatment of Wilms tumor in low-income countries: challenges and potential solutions. <i>Future Oncology</i> , 2013, 9, 1057-1059.	1.1	7
133	Weaver syndrome and <i>EZH2</i> mutations: Clarifying the clinical phenotype. <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 2972-2980.	0.7	119
134	Gain of 1q is a marker of poor prognosis in Wilms' tumors. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 1065-1074.	1.5	54
135	Bilateral Wilms Tumor with <i>TP53</i> -Related Anaplasia. <i>Pediatric and Developmental Pathology</i> , 2013, 16, 217-223.	0.5	13
136	Challenges in incentivizing the pharmaceutical industry to supporting pediatric oncology clinical trials. <i>Clinical Investigation</i> , 2013, 3, 101-103.	0.0	2
137	miRNA Profiles as a Predictor of Chemosensitiveness in Wilms's Tumor Blastema. <i>PLoS ONE</i> , 2013, 8, e53417.	1.1	71
138	Abstract 3829: TP53 mutation status defines two distinct classes of diffuse anaplastic Wilms tumor.. , 2013, , .		0
139	Abstract B36: DNA methylation profiling describes Wilms tumor evolution from its precursor lesion. , 2013, , .		0
140	Pragmatic approach to quality metrics development in cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 60-60.	0.8	0
141	Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial. <i>Annals of Oncology</i> , 2012, 23, 2457-2463.	0.6	79
142	Population survival from childhood cancer in Britain during 1978-2005 by eras of entry to clinical trials. <i>Annals of Oncology</i> , 2012, 23, 2464-2469.	0.6	57
143	Consent to tissue banking for research: qualitative study and recommendations. <i>Archives of Disease in Childhood</i> , 2012, 97, 632-636.	1.0	8
144	A genome-wide association study identifies susceptibility loci for Wilms tumor. <i>Nature Genetics</i> , 2012, 44, 681-684.	9.4	72

#	ARTICLE	IF	CITATIONS
145	Reply to S. Stegmaier et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 4040-4041.	0.8	4
146	The contribution of chest CT-scan at diagnosis in children with unilateral Wilms's tumour. Results of the SIOP 2001 study. <i>European Journal of Cancer</i> , 2012, 48, 1060-1065.	1.3	53
147	Stratification of Wilms tumor by genetic and epigenetic analysis. <i>Oncotarget</i> , 2012, 3, 327-335.	0.8	101
148	<i>PAX3/FOXO1</i> Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification. <i>Journal of Clinical Oncology</i> , 2012, 30, 1670-1677.	0.8	297
149	ecancermedalscience. <i>Ecancermedalscience</i> , 2011, 5, 210.	0.6	16
150	4103 ORAL Doxorubicin Can Be Safely Omitted From the Treatment of Stage II/III, Intermediate Risk Histology Wilms Tumour – Results of the SIOP WT 2001 Randomised Trial, on Behalf of the SIOP Renal Tumours Study Group. <i>European Journal of Cancer</i> , 2011, 47, S284-S285.	1.3	1
151	4107 ORAL The State of Research Into Children With Cancer Across Europe: Results of Key Opinion Leaders Survey and Innovative Policy Strategies for the Next Decade. <i>European Journal of Cancer</i> , 2011, 47, S286.	1.3	0
152	171 INVITED The European Network for Cancer Research in Children and Adolescents (ENCCA) FP7 Project. <i>European Journal of Cancer</i> , 2011, 47, S41.	1.3	0
153	172 INVITED – Spread of Excellence™ (Dissemination) Activities of the European Network of Excellence for Cancer Research in Children and Adolescents (ENCCA). <i>European Journal of Cancer</i> , 2011, 47, S41-S42.	1.3	0
154	Suggested change in definitional criteria for stage I Wilms tumour treated by surgery only – Response. <i>Pediatric Blood and Cancer</i> , 2011, 56, 169-170.	0.8	0
155	Mesoblastic nephroma: A report of the United Kingdom children's cancer and leukaemia group (CCLG). <i>Pediatric Blood and Cancer</i> , 2011, 56, 744-748.	0.8	58
156	Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group. <i>Pediatric Blood and Cancer</i> , 2011, 56, 733-737.	0.8	125
157	Molecular profiling reveals frequent gain of <i>MYCN</i> and anaplasia-specific loss of 4q and 14q in wilms tumor. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 982-995.	1.5	54
158	Management of adults with Wilms's tumour: recommendations based on international consensus. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1107-1115.	1.1	37
159	DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. <i>Journal of Medical Genetics</i> , 2011, 48, 273-278.	1.5	312
160	Long-term Risks of Subsequent Primary Neoplasms Among Survivors of Childhood Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2311.	3.8	289
161	Renal Tumors in Children Aged 10–16 Years: A Report from the United Kingdom Children's Cancer and Leukaemia Group. <i>Pediatric and Developmental Pathology</i> , 2011, 14, 189-193.	0.5	32
162	Wilms Tumor. , 2011, , 3947-3950.		0

#	ARTICLE	IF	CITATIONS
163	Abstract 5343: Aberrant activation of hedgehog signaling confers a poor prognosis in embryonal and fusion gene negative alveolar rhabdomyosarcoma. , 2011, , .		0
164	Incidence and outcomes of patients with late recurrence of Wilms tumor (WT): The international experience.. Journal of Clinical Oncology, 2011, 29, 9544-9544.	0.8	0
165	Research and Drug Development in Paediatric Oncology. , 2010, , 155-159.		0
166	Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood, 2010, 115, 1765-1767.	0.6	142
167	Hereditary leiomyomatosis and renal cell carcinoma: very early diagnosis of renal cancer in a paediatric patient. Familial Cancer, 2010, 9, 239-243.	0.9	56
168	Nephrectomyâ€”only for Wilms tumour: Negotiating the tangled web requires multiâ€”professional input. Pediatric Blood and Cancer, 2010, 54, 865-866.	0.8	5
169	Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene, 2010, 29, 6323-6330.	2.6	107
170	MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. British Journal of Cancer, 2010, 102, 1769-1777.	2.9	110
171	Reply to J.R. Anderson et al. Journal of Clinical Oncology, 2010, 28, e589-e590.	0.8	2
172	Fusion Geneâ€”Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma. Journal of Clinical Oncology, 2010, 28, 2151-2158.	0.8	426
173	Subtype-Specific <i>FBXW7</i> Mutation and <i>MYCN</i> Copy Number Gain in Wilms' Tumor. Clinical Cancer Research, 2010, 16, 2036-2045.	3.2	69
174	Constitutional translocation breakpoint mapping by genome-wide paired-end sequencing identifies HACE1 as a putative Wilms tumour susceptibility gene. Journal of Medical Genetics, 2010, 47, 342-347.	1.5	47
175	Extent of Alcohol Consumption among Adult Survivors of Childhood Cancer: The British Childhood Cancer Survivor Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1174-1184.	1.1	30
176	Long-term Cause-Specific Mortality Among Survivors of Childhood Cancer. JAMA - Journal of the American Medical Association, 2010, 304, 172.	3.8	375
177	Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncology, The, 2010, 11, 129-135.	5.1	334
178	Frequent Long-Range Epigenetic Silencing of Protocadherin Gene Clusters on Chromosome 5q31 in Wilms' Tumor. PLoS Genetics, 2009, 5, e1000745.	1.5	129
179	Expression of Hepatocyte Growth Factor and Its Receptor Met in Wilms' Tumors and Nephrogenic Rests Reflects Their Roles in Kidney Development. Clinical Cancer Research, 2009, 15, 2723-2730.	3.2	8
180	Loss of Heterozygosity at 2q37 in Sporadic Wilms' Tumor: Putative Role for <i>miR-562</i>. Clinical Cancer Research, 2009, 15, 5985-5992.	3.2	56

#	ARTICLE	IF	CITATIONS
181	Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 455-467.	1.5	98
182	Seeking consent to tissue banking: a survey of health professionals in childhood cancer. <i>European Journal of Cancer Care</i> , 2009, 18, 391-400.	0.7	10
183	Pregnancy Outcomes among Adult Survivors of Childhood Cancer in the British Childhood Cancer Survivor Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2239-2247.	1.1	127
184	Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1â€³ clinical trials: A Childrenâ€™s Cancer and Leukaemia Group (CCLG) study. <i>European Journal of Cancer</i> , 2009, 45, 819-826.	1.3	50
185	Treatment of relapsed Wilms tumors: lessons learned. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1807-1815.	1.1	77
186	Value and difficulties of a common European strategy for recurrent Wilmsâ€™ tumor. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 693-696.	1.1	8
187	Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. <i>British Journal of Haematology</i> , 2008, 140, 191-196.	1.2	34
188	Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1130-1134.	0.8	151
189	Second primary neoplasms in survivors of Wilms' tumourâ€”A population-based cohort study from the British Childhood Cancer Survivor Study. <i>International Journal of Cancer</i> , 2008, 122, 2085-2093.	2.3	59
190	Long-term population-based risks of breast cancer after childhood cancer. <i>International Journal of Cancer</i> , 2008, 123, 2156-2163.	2.3	18
191	Outcome After Pulmonary Radiotherapy in Wilms' Tumor Patients With Pulmonary Metastases at Diagnosis: A UK Children's Cancer Study Group, Wilms' Tumour Working Group Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 175-180.	0.4	32
192	Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. <i>Nature Genetics</i> , 2008, 40, 1329-1334.	9.4	154
193	Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study*. <i>British Journal of Haematology</i> , 2008, 141, 840-847.	1.2	170
194	T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. <i>Clinical Immunology</i> , 2008, 128, 148-154.	1.4	20
195	Clinical trials for children with cancer in Europe â€” Still a long way from harmonisation: A report from SIOP Europe. <i>European Journal of Cancer</i> , 2008, 44, 2106-2111.	1.3	31
196	Improving recruitment to clinical trials for cancer in childhood. <i>Lancet Oncology</i> , The, 2008, 9, 392-399.	5.1	50
197	Treating Burkitt's lymphoma in Malawi, Cameroon, and Ghana. <i>Lancet Oncology</i> , The, 2008, 9, 512-513.	5.1	40
198	Tissue Samples as â€”Giftsâ€™ for Research: A Qualitative Study of Families and Professionals. <i>Medical Law International</i> , 2008, 9, 131-150.	0.4	26

#	ARTICLE	IF	CITATIONS
199	Human Tissue and the Public™: The Case of Childhood Cancer Tumour Banking. <i>BioSocieties</i> , 2008, 3, 57-80.	0.8	35
200	Childhood papillary thyroid cancer as second malignancy after successful treatment of rhabdomyosarcoma. <i>Acta Oncologica</i> , 2008, 47, 469-472.	0.8	6
201	Perilobar Nephrogenic Rests Are Nonobligate Molecular Genetic Precursor Lesions of Insulin-Like Growth Factor-II-Associated Wilms Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 7635-7644.	3.2	30
202	c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours. <i>Journal of Clinical Pathology</i> , 2007, 60, 1226-1231.	1.0	24
203	What can we learn from geographical comparisons of childhood cancer survival?. <i>British Journal of Cancer</i> , 2007, 96, 1493-1497.	2.9	6
204	Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours. <i>Journal of Clinical Pathology</i> , 2007, 61, 95-102.	1.0	8
205	Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 130-134.	4.3	86
206	Role for Amplification and Expression of Glypican-5 in Rhabdomyosarcoma. <i>Cancer Research</i> , 2007, 67, 57-65.	0.4	94
207	Alternately spliced <i>WT1</i> antisense transcripts interact with <i>WT1</i> sense RNA and show epigenetic and splicing defects in cancer. <i>Rna</i> , 2007, 13, 2287-2299.	1.6	71
208	Multifaceted Dysregulation of the Epidermal Growth Factor Receptor Pathway in Clear Cell Sarcoma of the Kidney. <i>Clinical Cancer Research</i> , 2007, 13, 4360-4364.	3.2	35
209	Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours. <i>European Journal of Cancer</i> , 2007, 43, 2074-2081.	1.3	12
210	Consent for childhood cancer tissue banking in the UK: the effect of the Human Tissue Act 2004. <i>Lancet Oncology</i> , The, 2007, 8, 266-272.	5.1	17
211	UK childhood cancer survival falling behind rest of EU?. <i>Lancet Oncology</i> , The, 2007, 8, 662-663.	5.1	8
212	Chairperson's Introduction. <i>European Journal of Cancer</i> , Supplement, 2007, 5, 201.	2.2	0
213	Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 607-615.	1.5	19
214	Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. <i>Journal of Pathology</i> , 2007, 211, 52-59.	2.1	60
215	A prospective study of admissions for febrile neutropenia in secondary paediatric units in South East England. <i>Pediatric Blood and Cancer</i> , 2007, 49, 678-681.	0.8	21
216	Comparative genomic hybridization and BUB1B mutation analyses in childhood cancers associated with mosaic variegated aneuploidy syndrome. <i>Cancer Letters</i> , 2006, 239, 234-238.	3.2	39

#	ARTICLE	IF	CITATIONS
217	Incidence of and survival from Wilms's tumour in adults in Europe: Data from the EURO CARE study. <i>European Journal of Cancer</i> , 2006, 42, 2363-2368.	1.3	56
218	Malignant renal tumours incidence and survival in European children (1978-1997): Report from the Automated Childhood Cancer Information System project. <i>European Journal of Cancer</i> , 2006, 42, 2103-2114.	1.3	197
219	Geographical comparison of cancer survival in European children (1988-1997): Report from the Automated Childhood Cancer Information System project. <i>European Journal of Cancer</i> , 2006, 42, 1972-1980.	1.3	65
220	Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms's tumour: Results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. <i>European Journal of Cancer</i> , 2006, 42, 2554-2562.	1.3	152
221	Cancer in children and adolescents in Europe: Developments over 20 years and future challenges. <i>European Journal of Cancer</i> , 2006, 42, 2183-2190.	1.3	156
222	Wilms' tumor with intracaval thrombus in the UK Children's Cancer Study Group UKW3 trial. <i>Journal of Pediatric Surgery</i> , 2006, 41, 382-387.	0.8	93
223	Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. <i>Genomics</i> , 2006, 87, 298-306.	1.3	94
224	Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. <i>Journal of Pathology</i> , 2006, 210, 49-58.	2.1	112
225	Diagnosing renal tumors: does every profile paint a story?. <i>Pediatric Blood and Cancer</i> , 2006, 46, 716-717.	0.8	0
226	Multiple pathways to Wilms tumor: How much is genetic?. <i>Pediatric Blood and Cancer</i> , 2006, 47, 232-234.	0.8	11
227	Clinical Features of Molecular Pathology of Solid Tumors in Childhood. <i>ChemInform</i> , 2006, 37, no.	0.1	0
228	Nascent pre-rRNA overexpression correlates with an adverse prognosis in alveolar rhabdomyosarcoma. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 839-845.	1.5	50
229	Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice. <i>Archives of Disease in Childhood</i> , 2006, 91, 995-999.	1.0	136
230	Amplification and Overexpression of CACNA1E Correlates with Relapse in Favorable Histology Wilms' Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 7284-7293.	3.2	52
231	Blastemal Expression of Type I Insulin-Like Growth Factor Receptor in Wilms' Tumors Is Driven by Increased Copy Number and Correlates with Relapse. <i>Cancer Research</i> , 2006, 66, 11148-11155.	0.4	47
232	Wt1 is not essential for hematopoiesis in the mouse. <i>Leukemia Research</i> , 2005, 29, 803-812.	0.4	19
233	Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. <i>British Journal of Cancer</i> , 2005, 92, 1358-1365.	2.9	41
234	Loci other than 21q22.12 (RUNX1) and 16q21-23.2 cause familial AML. <i>Leukemia</i> , 2005, 19, 465-466.	3.3	3

#	ARTICLE	IF	CITATIONS
235	Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. <i>Leukemia</i> , 2005, 19, 1276-1278.	3.3	71
236	A WT1 exon 1 mutation in a child diagnosed with Denys-Drash syndrome. <i>Pediatric Nephrology</i> , 2005, 20, 81-85.	0.9	24
237	Relationship Between MYCN Copy Number and Expression in Rhabdomyosarcomas and Correlation With Adverse Prognosis in the Alveolar Subtype. <i>Journal of Clinical Oncology</i> , 2005, 23, 880-888.	0.8	106
238	Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. <i>Journal of Medical Genetics</i> , 2005, 42, 147-151.	1.5	101
239	Effect of media portrayals of removal of children's tissue on UK tumour bank. <i>BMJ: British Medical Journal</i> , 2005, 331, 401-403.	2.4	15
240	Clinical features of molecular pathology of solid tumours in childhood. <i>Lancet Oncology</i> , The, 2005, 6, 421-430.	5.1	16
241	Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study. <i>Clinical Cancer Research</i> , 2005, 11, 5893-5899.	3.2	53
242	Frequency and Heritability of WT1 Mutations in Nonsyndromic Wilms' Tumor Patients: A UK Children's Cancer Study Group Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 4140-4146.	0.8	93
243	Chronic hepatotoxicity following 6-thioguanine therapy for childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2004, 125, 410-411.	1.2	18
244	Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 65-79.	1.5	48
245	Success of clinical trials in childhood Wilms' tumour around the world. <i>Lancet</i> , The, 2004, 364, 1468-1470.	6.3	41
246	The molecular basis of children's cancers. , 2004, , 25-51.		1
247	Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case. <i>Cancer Genetics and Cytogenetics</i> , 2003, 140, 73-77.	1.0	35
248	Expression profiling targeting chromosomes for tumor classification and prediction of clinical behavior. <i>Genes Chromosomes and Cancer</i> , 2003, 38, 207-214.	1.5	18
249	Expression profile of wild-type ETV6 in childhood acute leukaemia. <i>British Journal of Haematology</i> , 2003, 122, 94-98.	1.2	30
250	PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. <i>British Journal of Cancer</i> , 2003, 89, 327-332.	2.9	93
251	WT1 expression does not disrupt myogenic differentiation in C2C12 murine myoblasts or in human rhabdomyosarcoma. <i>Experimental Cell Research</i> , 2003, 287, 155-165.	1.2	4
252	Older Age Is an Adverse Prognostic Factor in Stage I, Favorable Histology Wilms' Tumor Treated With Vincristine Monochemotherapy: A Study by the United Kingdom Children's Cancer Study Group, Wilms' Tumor Working Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 3269-3275.	0.8	101

#	ARTICLE	IF	CITATIONS
253	Controversies and advances in the management of Wilms' tumour. Archives of Disease in Childhood, 2002, 87, 241-244.	1.0	81
254	Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet, The, 2002, 360, 385-386.	6.3	57
255	EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin) chemotherapy selected for multidrug resistance modulation. European Journal of Cancer, 2002, 38, 2422-2427.	1.3	7
256	In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood, 2002, 99, 3801-3805.	0.6	247
257	High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. British Journal of Cancer, 2001, 85, 1746-1752.	2.9	24
258	PAX3-FKHR Induces Morphological Change and Enhances Cellular Proliferation and Invasion in Rhabdomyosarcoma. American Journal of Pathology, 2001, 159, 1089-1096.	1.9	67
259	Gain of 1q Is Associated with Adverse Outcome in Favorable Histology Wilms' Tumors. American Journal of Pathology, 2001, 158, 393-398.	1.9	127
260	Congenital alveolar rhabdomyosarcoma. Cancer, 2001, 91, 606-612.	2.0	49
261	Cytogenetic abnormalities in 42 rhabdomyosarcoma: A United Kingdom cancer cytogenetics group study. Medical and Pediatric Oncology, 2001, 36, 259-267.	1.0	70
262	Case of interstitial 12q deletion in association with Wilms tumor. American Journal of Medical Genetics Part A, 2001, 104, 246-249.	2.4	13
263	Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?. British Journal of Cancer, 2001, 85, 831-835.	2.9	107
264	Molecular cytogenetic analysis consistently identifies translocations involving chromosomes 1, 2 and 15 in five embryonal rhabdomyosarcoma cell lines and a PAX-FOXO1A fusion gene negative alveolar rhabdomyosarcoma cell line. Cytogenetic and Genome Research, 2001, 95, 134-142.	0.6	14
265	Comparative expressed sequence hybridization to chromosomes for tumor classification and identification of genomic regions of differential gene expression. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9197-9202.	3.3	53
266	Cytogenetic abnormalities in 42 rhabdomyosarcoma: A United Kingdom cancer cytogenetics group study. Medical and Pediatric Oncology, 2001, 36, 259-267.	1.0	3
267	A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. , 2000, 28, 220-226.		75
268	Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2. British Journal of Cancer, 2000, 83, 177-183.	2.9	53
269	Familial Wilms tumour resulting from WT1 mutation: intronic polymorphism causing artefactual constitutional homozygosity. Journal of Medical Genetics, 2000, 37, 377-380.	1.5	14
270	Penetrance of Mutations in the Familial Wilms Tumor Gene FWT1. Journal of the National Cancer Institute, 2000, 92, 650-652.	3.0	19



#	ARTICLE	IF	CITATIONS
271	PRINCIPLES OF WILMS' TUMOR BIOLOGY. Urologic Clinics of North America, 2000, 27, 423-434.	0.8	40
272	A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. Genes Chromosomes and Cancer, 2000, 28, 220-6.	1.5	29
273	BIRICODAR (VX-710; Incelâ„¢): an effective chemosensitizer in neuroblastoma. British Journal of Cancer, 1999, 80, 1190-1196.	2.9	45
274	The Wilms tumour gene, WT1 , in normal and abnormal nephrogenesis. Pediatric Nephrology, 1999, 13, 620-625.	0.9	43
275	Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes and Cancer, 1999, 26, 275-285.	1.5	145
276	Disruption of Imprinted Genes at Chromosome Region 11p15.5 in Paediatric Rhabdomyosarcoma. Neoplasia, 1999, 1, 340-348.	2.3	85
277	Molecular Genetics of Wilms Tumor. , 1999, , 123-129.		0
278	Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes and Cancer, 1999, 26, 275-85.	1.5	49
279	Confirmation of FWT1 as a Wilmsâ€™ tumour susceptibility gene and phenotypic characteristics of Wilmsâ€™ tumour attributable to FWT1. Human Genetics, 1998, 103, 547-556.	1.8	48
280	Wilms' Tumor (WT1) Gene Mutations Occur Mainly in Acute Myeloid Leukemia and May Confer Drug Resistance. Blood, 1998, 91, 2961-2968.	0.6	164
281	Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood, 1998, 91, 2961-8.	0.6	55
282	Malignant Origin of the Stromal Component of Wilms' Tumor. Journal of the National Cancer Institute, 1997, 89, 1089-1091.	3.0	7
283	The Wilms Tumour Gene<i>WT1</i>in Leukaemia. Leukemia and Lymphoma, 1997, 27, 207-220.	0.6	27
284	Biology of Wilms' tumour. Lancet, The, 1997, 349, 663-664.	6.3	16
285	The familial Wilms' tumour susceptibility gene, FWT1, may not be a tumour suppressor gene. Oncogene, 1997, 14, 3099-3102.	2.6	17
286	Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation. British Journal of Haematology, 1997, 97, 165-168.	1.2	33
287	Differential splicing of exon 5 of the Wilms tumour (WT1) gene. Genes Chromosomes and Cancer, 1997, 19, 256-266.	1.5	39
288	Molecular Genetic Pathways to Wilms Tumor. Critical Reviews in Oncogenesis, 1997, 8, 1-27.	0.2	23

#	ARTICLE	IF	CITATIONS
289	Amplification of the t(2; 13) and t(1; 13) translocations of alveolar rhabdomyosarcoma in small formalin-fixed biopsies using a modified reverse transcriptase polymerase chain reaction. <i>American Journal of Pathology</i> , 1997, 150, 477-82.	1.9	32
290	Response of previously untreated metastatic rhabdomyosarcoma to combination chemotherapy with carboplatin, epirubicin and vincristine. <i>European Journal of Cancer</i> , 1996, 32, 821-825.	1.3	19
291	Mutations in the Wilms' tumor gene WT1 in leukemias. <i>Blood</i> , 1996, 87, 2171-2179.	0.6	153
292	Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. , 1996, 17, 7-13.		50
293	Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21. <i>Nature Genetics</i> , 1996, 13, 461-463.	9.4	166
294	Mutational Analysis of the Wilms' Tumor (WT1) Gene. , 1996, 6, 141-147.		0
295	Wilms tumour and other genetic causes of renal cancer. , 1996, , 105-122.		0
296	Mutations in the Wilms' tumor gene WT1 in leukemias. <i>Blood</i> , 1996, 87, 2171-9.	0.6	45
297	Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. <i>Cancer Research</i> , 1996, 56, 3220-4.	0.4	122
298	Association of Wilms' Tumor with Primary Brain Tumor in Siblings. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995, 54, 214-223.	0.9	8
299	Mutations in the Wilms' tumour gene, WT1. What do they mean?. <i>European Journal of Cancer</i> , 1995, 31, 2138-2140.	1.3	5
300	The Wilms tumour (WT1) gene is mutated in a secondary leukaemia in a WAGR patient. <i>Human Molecular Genetics</i> , 1994, 3, 1633-1637.	1.4	62
301	The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. <i>Mechanisms of Development</i> , 1993, 40, 85-97.	1.7	530
302	Equivalent expression of paternally and maternally inherited WT1 alleles in normal fetal tissue and Wilms' tumours. <i>Oncogene</i> , 1992, 7, 635-41.	2.6	49
303	Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis. <i>Oncogene</i> , 1991, 6, 2211-20.	2.6	58
304	The candidate Wilms' tumour gene is involved in genitourinary development. <i>Nature</i> , 1990, 346, 194-197.	13.7	814
305	Wilms' tumour as a paradigm for the relationship of cancer to development. <i>Cancer Surveys</i> , 1990, 9, 555-78.	1.5	13
306	Severe osteoporosis with spontaneous fracture in a young diabetic woman. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1986, 3, 98-99.	0.2	1

#	ARTICLE	IF	CITATIONS
307	Continuous Ecg Monitoring of Children with Cancer Receiving Domperidone. Pediatric Hematology and Oncology, 1986, 3, 343-346.	0.3	1
308	Insulin oedema. Postgraduate Medical Journal, 1986, 62, 665-668.	0.9	28